Bharat Biotech seals deal to supply COVAXIN vaccine to US; Ocugen its commercial partner

In a proud moment for India, Ocugen Inc and Bharat Biotech have anunced a definitive agreement to co-develop, supply and commercialise Bharat Biotech's Covaxin. It will be an vanced st whole-virion inactivated COVID-19 vaccine candidate for US market, companies said in a joint statement on Wednesday.

Pennsylvania-based Ocugen will have rights to market vaccine. Under terms of agreement, company will be responsible for clinical development, regulatory approval (including Emergency Use Authorisation ) and commercialisation for US market. On or hand, Bharat Biotech will supply initial doses to be used in US upon Ocugen's receipt of a EUA and support techlogy transfer for manufacturing in states. US-firm would retain 45% of profits and will share profits from sale of Covaxin in US market with Bharat Biotech.

RE | 'Great Step Ahe': Bharat Biotech Hails Rs 35,000 Cr Budget Allocation For COVID Vaccine

Bharat Biotech CMD Krishna Ella said that COVID-19 pandemic has affected humanity at large and Bharat Biotech's goal is to provide global access to vaccines developed by m.

" COVID-19 pandemic has affected humanity at large. As a company determined to protect global public health, it has always been important for us to develop vaccines for a global cause. Our goal for all vaccines developed at Bharat Biotech is to provide global access. Covaxin has generated excellent safety data with robust immune responses to multiple viral proteins that persist," he said, reported PTI.

Ocugen Chairman Shankar Musunuri said that evaluation of Covaxin has resulted in long-term persistence of immune responses to multiple viral proteins.

" evaluation of Covaxin has resulted in several unique product characteristics including long-term persistence of immune responses to multiple viral proteins, as opposed to only spike protein, and has demonstrated bro-spectrum neutralising capability with heterologous SARS-CoV-2 strains, thus potentially reducing or eliminating escape mutants," Ocugen Chairman Shankar Musunuri said.

RE | Bharat Biotech Issues Guideline, vises Pregnant Or Breastfeeding Women To Avoid Covaxin

Bharat Biotech And Ocugen To Co-Develop COVAXIN 

On December 23, For first time, US-based biopharmaceutical firm Ocugen Inc and Bharat Biotech anunced about co-development of  latter's COVID-19 vaccine candidate, COVAXIN, for United States' market. y signed a binding letter of intent to co-develop vaccine.

RE | Bharat Biotech & SII Issue Joint Statement; Pledge Global Access To COVID-19 Vaccines

RE | Bharat Biotech And Ocugen To Co-Develop COVAXIN For U.S. Market

(With PTI Inputs)